BlackRock wasn't alone. Last week, something interesting happened on CNBC. Host Scott Wapner was interviewing Jeffrey Gundlach - they call him the Bond King. Wapner lobbed him a softball about ...

Dow Jones Top Company Headlines at 11 AM ET: Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion | Oracle ... Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 ...

Dow Jones Top Financial Services Headlines at 11 AM ET: Fed's Bostic Sees Little Reason to Cut Rates Further for Now | Treasurys ... The Atlanta Fed president, Raphael Bostic, said risks of weaker ...

Dow Jones Top Markets Headlines at 11 AM ET: Fed's Bostic Sees Little Reason to Cut Rates Further for Now | U.S. ... The Atlanta Fed president, Raphael Bostic, said risks of weaker employment outcomes ...

Dow Jones Top Energy Headlines at 11 AM ET: Oil Falls, Giving Up Overnight Gains | The ... Crude futures fell, giving up overnight gains, on market concerns about seasonal loosening of oil balances.

But it's not just a deficit of numbers; it's an opportunity deficit. Today, venture capital and private equity are capturing the biggest growth years of companies, leaving individuals to sort through ...

There are instances when a gift would be exempt from the Medicaid look-back period, including one made by a parent to their child who is blind, disabled or under the age of 21 or to what is termed a ...

Pfizer has agreed to pay up to $7.3 billion for weight-loss drug developer Metsera in a deal that gets the New York drugmaker back into the burgeoning market for obesity drugs.

Getting back to the 178 stocks in the S&P 500 that have beaten the index's 14.4% total return this year, 15 of them have had their forward price-to-earnings ratios decline. These are ratios of prices ...

Oracle's stock is up 85% this year, and two new CEOs will be tasked with furthering the company's momentum.

Kyowa Kirin differentiates itself with its niche specialty in rare diseases, evidenced by both its existing core drug Crysvita (for rare metabolic bone diseases) and Poteligeo (for rare blood cancers) ...

Here's the headline: You'll likely never run out of dough, given your guaranteed income of $110,400 a year and a 4% withdrawal rate, assuming a 10% nominal return on your stocks (7% after inflation is ...